Novo Nordisk A/S

CPSE:NOVO B Voorraadrapport

Marktkapitalisatie: DKK 3.2t

Novo Nordisk Beheer

Beheer criteriumcontroles 3/4

De CEO Novo Nordisk is Lars Jorgensen, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. bezit rechtstreeks 0.002% van de aandelen van het bedrijf, ter waarde DKK 65.85M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 6.7 jaar.

Belangrijke informatie

Lars Jorgensen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO7.8yrs
Eigendom CEO0.002%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur6.7yrs

Recente managementupdates

Recent updates

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Jul 05
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04
Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28
The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18
Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30
Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12
Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24
Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Analyse CEO-vergoeding

Hoe is Lars Jorgensen's beloning veranderd ten opzichte van Novo Nordisk's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

DKK 95b

Jun 30 2024n/an/a

DKK 90b

Mar 31 2024n/an/a

DKK 89b

Dec 31 2023n/an/a

DKK 84b

Sep 30 2023n/an/a

DKK 75b

Jun 30 2023n/an/a

DKK 67b

Mar 31 2023n/an/a

DKK 61b

Dec 31 2022DKK 60mDKK 17m

DKK 56b

Sep 30 2022n/an/a

DKK 53b

Jun 30 2022n/an/a

DKK 51b

Mar 31 2022n/an/a

DKK 49b

Dec 31 2021DKK 58mDKK 17m

DKK 48b

Sep 30 2021n/an/a

DKK 46b

Jun 30 2021n/an/a

DKK 44b

Mar 31 2021n/an/a

DKK 43b

Dec 31 2020DKK 57mDKK 14m

DKK 42b

Sep 30 2020n/an/a

DKK 42b

Jun 30 2020n/an/a

DKK 41b

Mar 31 2020n/an/a

DKK 40b

Dec 31 2019DKK 55mDKK 14m

DKK 39b

Sep 30 2019n/an/a

DKK 39b

Jun 30 2019n/an/a

DKK 38b

Mar 31 2019n/an/a

DKK 38b

Dec 31 2018DKK 41mDKK 11m

DKK 39b

Sep 30 2018n/an/a

DKK 38b

Jun 30 2018n/an/a

DKK 39b

Mar 31 2018n/an/a

DKK 39b

Dec 31 2017DKK 32mDKK 9m

DKK 38b

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Lars redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Danish markt.

Compensatie versus inkomsten: De vergoeding van Lars is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Lars Jorgensen (58 yo)

7.8yrs

Tenure

DKK 60,100,000

Compensatie

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Lars Jorgensen
President7.8yrsDKK 60.10m0.0021%
DKK 65.8m
Karsten Knudsen
Executive VP6.8yrsDKK 21.50m0.000010%
DKK 315.1k
Henrik Wulff
Executive VP of Product Supplyno dataDKK 22.00m0.000060%
DKK 1.9m
Camilla Sylvest
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Boardno dataDKK 21.30mgeen gegevens
Martin Lange
Executive VP of Development & Member of the Management Board3.8yrsDKK 20.90mgeen gegevens
Marcus Schindler
EVP of Research & Early Development3.7yrsDKK 20.90mgeen gegevens
Maziar Doustdar
Executive VP of International Operations & Member of the Management Boardno datageen gegevens0.0011%
DKK 35.6m
Douglas Langa
Executive VP of North America Operations & Member of Management Boardno datageen gegevensgeen gegevens
Ludovic Helfgott
Executive VPno datageen gegevensgeen gegevens
Tania Sabroe
Executive VP of Global People & Organisation and Member of Management Board1.7yrsgeen gegevensgeen gegevens
David Moore
Executive VP of Corporate Development & Member of Management Board1.7yrsgeen gegevensgeen gegevens
Jacob Martin Rode
Head of Investor Relationsno datageen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NOVO B wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Sylvie Gregoire
Independent Director9.7yrsDKK 1.80mgeen gegevens
Helge Lund
Independent Chairman of the Board7.7yrsDKK 3.10mgeen gegevens
Henrik Poulsen
Vice Chairman of the Board3.7yrsDKK 2.00mgeen gegevens
Laurence Debroux
Independent Director5.7yrsDKK 2.00mgeen gegevens
Martin MacKay
Independent Director6.7yrsDKK 1.70mgeen gegevens
Andreas Fibig
Independent Director6.7yrsDKK 1.40mgeen gegevens
Kasim Kutay
Non-Independent Director7.7yrsDKK 1.20mgeen gegevens
Christina Law
Independent Director2.7yrsDKK 1.30mgeen gegevens
Liselotte Hyveled
Employee Representative Director2.7yrsDKK 800.00k0%
DKK 0
Mette Jensen
Employee Non-Independent Representative Director6.7yrsDKK 1.20mgeen gegevens
Thomas Rantzau
Employee Representative Non-Independent Director6.8yrsDKK 1.00mgeen gegevens
Elisabeth Christensen
Employee Representative Director2.7yrsDKK 800.00kgeen gegevens

6.7yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NOVO B wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).